Development and manufacturing partner for external innovation in oral care
ORALABX works with R&D, external innovation and partnership teams — from early technical assessment through prototype, evaluation and commercial supply.
Feasibility input on formats, actives and processing constraints, so that the specification is written against what can actually be manufactured and shipped.
Alcohol removal, preservative system changes, flavour and sensory rebuilding, cost-structure reconstruction, or transfer into a different format.
Taking a defined consumer occasion — travel, post-meal, away from the sink — and building the product, the dose and the pack around it.
Taking an already-defined product into validated, documented and repeatable production.
US OTC drug products
Ingredient or active discovery
Devices, electronics and diagnostics
These are the areas where we hold working experience rather than general capability.
Zinc Citrate + Xylitol is the primary alcohol-free development direction. Zinc PCA is evaluated only when a defined project brief and target-market pathway support it.
PAP suspension development focuses on dispersion control, appearance, sensory balance, stability observation and packaging compatibility before commercial scale-up.
Controlled low-peroxide development uses an established commercial formula route, with flavor adjustment and removal of non-essential flavor components evaluated without changing the core system.
Spray dosing and atomiser selection, single-use sachet and stick-pack filling, and travel pack sizes designed for use away from a sink.
Flavour systems for high-humectant and alcohol-free bases, where a flavour that performs in a standard base will not transfer directly.
We confirm what is technically and commercially possible before development starts, including regulatory pathway, format limits and packaging constraints.
Two to three directions are usually developed in parallel rather than one, so the decision is made on comparison.
Prototype samples for internal evaluation, followed by a revision round against structured feedback.
Stability, compatibility and applicable third-party testing before any commitment to production.
Technical assessment → prototype sampling → structured evaluation → 10,000+ units per SKU commercial manufacturing when qualified.
Development, testing and manufacturing stages can be scoped separately within a commercial development programme.
Incoming material inspection, in-process quality control, finished-product quality control, pH, microbiological testing, packaging compatibility, leak testing, and finished-product stability over 90 to 180 days.
Carried out at internationally accredited (ISO/IEC 17025) laboratories, according to project requirements and applicable test methods.
QB/T 2738, GB 15979 — S. mutans, P. gingivalis, F. nucleatum
We state what documentation exists and at which stage it becomes available, rather than offering an undefined qualification pack.
Project-specific formulation rights and exclusivity arrangements are agreed as part of the commercial programme. ORALABX retains its pre-existing technical know-how, development platforms, manufacturing methods and other background IP. Ownership boundaries are defined before development begins rather than assumed afterwards.
We do not publish client names, brands or project details, including for completed work. Any case material on this site is anonymised.
We are used to working with intermediaries who cannot disclose the end client during screening, and we do not require disclosure in order to respond to a technical brief.
Commercial mouthwash and breath spray production is executed by the designated Fujian production facility. Formula consulting, development support, sample execution, commercial manufacturing and document issuance are confirmed separately for each project.
Liquid oral-care capacity is planned against qualified project scope. Toothpaste concepts are evaluated separately and require confirmation of the licensed manufacturing route before any production commitment.
Approximately 45–60 calendar days after formula, packaging, artwork, deposit and production requirements are confirmed.
North America is our largest export market, with additional supply to Europe and the UK, the Middle East and Australia.
If you are screening partners for a defined need, a short written brief is enough to get a substantive answer. You do not need to identify your client, and no NDA is required for an initial discussion.
We reply in writing within three business days, including when the answer is that the need falls outside our scope.
